VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO TAT 2021 | Safety of continued dosing of MEDI1191

Omid Hamid, MD, Cedars-Sinai Medical Center, Los Angeles, CA, discusses the safety of continued dosing of MEDI1191 (IL-12 mRNA) during the Phase I trial (NCT03946800), in which patients with solid tumors were intratumorally injected with MEDI1191 in combination with durvalumab. Intratumoral injection of MEDI1191 resulted in localized production of IL-12 in the tumor, stimulating immune cell and IFN gamma production, as well as inducing cytotoxic T cell activity into the tumor area. Despite some toxicity seen in continued dosing, early detection demonstrated the safety of MEDI1191. This interview took place during the ESMO TAT 2021 conference.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter